Duke University spinout Cereius has signed up BioInnovation Capital to its series A round as it looks to commercialise a radiotherapeutic approach for brain tumours.
Cereius, a US-based brain tumour treatment spinout from Duke University, closed a $6.5m series A round on Wednesday led by venturing firm BioInnovation Capital with contributions from unnamed private investors.
The spinout has also obtained a $250,000 loan from state-backed research agency North Carolina Biotechnology Center.
Founded in 2017, Cereius is developing a radiotherapeutic approach for solid metastasis tumours in the brain. The technique bypasses the blood-brain barrier, a semi-permeable membrane that separates blood in the brain from fluids elsewhere…
